Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais

被引:57
作者
Lynch, JA
deSouza, R
Robb, MD
Markowitz, L
Nitayaphan, S
Sapan, CV
Mann, DL
Birx, DL
Cox, JH
机构
[1] Henry M Jackson Fdn Adv Mil Med, Rockville, MD 20850 USA
[2] Walter Reed Army Med Ctr, Dept Pediat, Div Infect Dis, Washington, DC 20307 USA
[3] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Retrovirol, Washington, DC 20307 USA
[4] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand
[5] NABI Inc, Boca Raton, FL USA
[6] Univ Maryland, Div Immunogenet, Baltimore, MD 21201 USA
关键词
D O I
10.1086/515652
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A globally effective vaccine will need to elicit cytotoxic T lymphocytes (CTL) capable of recognizing diverse human immunodeficiency virus type I (HIV-1) clades. Study of the cellular immune responses of HIV-1-infected persons may allow predictions to be made regarding useful vaccine antigen components. The frequency and magnitude of CTL responses to clade E and B Gag, Pol- RT, Env, and Nef proteins were compared in 12 HLA-characterized, clade E-infected Thais and in 10 clade B-infected North Americans using vaccinia recombinant constructs for protein expression. While responses were detected against all proteins, they were most frequent and cross-reactive to Gag in both groups. Pol-RT was recognized less frequently in Thais than North Americans. Cross-clade protein recognition was common but not uniformly present among these HLA-disparate individuals. Population-specific CTL data are needed to adequately prepare for vaccine trials outside of North America and Europe.
引用
收藏
页码:1040 / 1046
页数:7
相关论文
共 43 条
[1]   HIV type 1 vaccine-induced cytotoxic T cell responses: Potential role in vaccine efficacy [J].
Ada, GL ;
McElrath, MJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (03) :205-210
[2]   DUAL INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 OF DISTINCT ENVELOPE SUBTYPES IN HUMANS [J].
ARTENSTEIN, AW ;
VANCOTT, TC ;
MASCOLA, JR ;
CARR, JK ;
HEGERICH, PA ;
GAYWEE, J ;
SANDERSBUELL, E ;
ROBB, ML ;
DAYHOFF, DE ;
THITIVICHIANLERT, S ;
NITAYAPHAN, S ;
MCNEIL, JG ;
BIRX, DL ;
MICHAEL, RA ;
BURKE, DS ;
MCCUTCHAN, FE .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :805-810
[3]   Sequences and phylogenetic analysis of the nef gene from Thai subjects harboring subtype E HIV-1 [J].
Artenstein, AW ;
Hegerich, PA ;
Beyrer, C ;
Rungruengthanakit, K ;
Michael, NL ;
Natpratan, C .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (06) :557-560
[4]  
Bergmann CC, 1996, J IMMUNOL, V157, P3242
[5]   Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians [J].
Betts, MR ;
Krowka, J ;
Santamaria, C ;
Balsamo, K ;
Gao, F ;
Mulundu, G ;
Luo, CW ;
NGandu, N ;
Sheppard, H ;
Hahn, BH ;
Allen, S ;
Frelinger, JA .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8908-8911
[6]   A METHOD FOR TYPING POLYMORPHISM AT THE HLA-A LOCUS USING PCR AMPLIFICATION AND IMMOBILIZED OLIGONUCLEOTIDE PROBES [J].
BUGAWAN, TL ;
APPLE, R ;
ERLICH, HA .
TISSUE ANTIGENS, 1994, 44 (03) :137-147
[7]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[8]   Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development [J].
Cao, HY ;
Kanki, P ;
Sankale, JL ;
DiengSarr, A ;
Mazzara, GP ;
Kalams, SA ;
Korber, B ;
Mboup, S ;
Walker, BD .
JOURNAL OF VIROLOGY, 1997, 71 (11) :8615-8623
[9]   Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand [J].
Carr, JK ;
Salminen, MO ;
Koch, C ;
Gotte, D ;
Artenstein, AW ;
Hegerich, PA ;
StLouis, D ;
Burke, DS ;
McCutchan, FE .
JOURNAL OF VIROLOGY, 1996, 70 (09) :5935-5943
[10]  
CEASE KB, 1994, ANNU REV IMMUNOL, V12, P923, DOI 10.1146/annurev.iy.12.040194.004423